Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

利厄替尼治疗EGFR T790M突变阳性NSCLC关键IIB期临床研究中，共计入组了 301 例经既往EGFR-TKI治疗后进展的EGFR T790M突变阳性或原发性EGFR T790M突变阳性局部 ...

今日，恒瑞医药宣布，公司收到国家药品监督管理局（以下简称 “国家药监局”）核准签发关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，将 ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung ...

Hope is not passive wishing but an active, dynamic process. According to Hope Theory, hope involves two components: agency and pathways. Agency is the belief in one’s capability to act ...

The company is currently developing HT-001 with intentions of submitting a new drug application via the 505(b)(2) regulatory pathway, according to the company website.

This discrepancy indicates that the etching procedure introduced extraneous conductive pathways unrelated to the VHE, thereby explaining why a reduced band gap had been observed in prior ...